Figure S2. Second Round Secondary Screening: Competitive-ABPP profiling with recombinant human (rh) LYPLA2 and endogenous mouse LYPLA1 and LYPLA2 in the mouse brain soluble proteome with 10 µM test compound (30 minutes) and the SH-specific FP-Rh ABPP probe (2 µM, 30 minutes).
Figure S2. Second Round Secondary Screening: Competitive-ABPP profiling with recombinant human (rh) LYPLA2 and endogenous mouse LYPLA1 and LYPLA2 in the mouse brain soluble proteome with 10 µM test compound (30 minutes) and the SH-specific FP-Rh ABPP probe (2 µM, 30 minutes).

Figure S2Second Round Secondary Screening: Competitive-ABPP profiling with recombinant human (rh) LYPLA2 and endogenous mouse LYPLA1 and LYPLA2 in the mouse brain soluble proteome with 10 µM test compound (30 minutes) and the SH-specific FP-Rh ABPP probe (2 µM, 30 minutes)

See Table S1 for quantified results and compound SIDs and structures. Fluorescent images shown in grey scale. (AID 652030).

From: Characterization of a Selective, Reversible Inhibitor of Lysophospholipase 2 (LYPLA2)

Cover of Probe Reports from the NIH Molecular Libraries Program
Probe Reports from the NIH Molecular Libraries Program [Internet].
Copyright Notice

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.